MacroGenics (MGNX) investor relations material

Executive summary

• Focused on developing antibody-based cancer therapeutics, with three proprietary candidates in clinical development and three FDA-approved products partnered or out-licensed.

• Divested manufacturing operations to focus on novel drug discovery and development, expecting up to $202.5 million in proceeds from the divestiture and expanded ZYNYZ royalty monetization.

• Strategic collaborations have provided over $1.6 billion in non-dilutive funding since inception.

• Transitioning to a fully outsourced manufacturing model for increased flexibility and cost advantages.

• Corporate restructuring will reduce headcount to approximately 135 employees, enhancing agility and focus on research and clinical development.

Financial highlights

• Total revenue for Q1 2026 was $20.8 million, up 58% from $13.2 million in Q1 2025, driven by higher contract manufacturing and royalty revenue.

• Net loss for Q1 2026 was $36.8 million, an improvement from $41.0 million in Q1 2025.

• Cash, cash equivalents, and marketable securities totaled $154.2 million at March 31, 2026, not including $60 million from Sagard and expected $122.5 million from Bora.

• Operating cash outflow was $35.8 million in Q1 2026, compared to $46.9 million in Q1 2025.

• Cost of manufacturing services increased to $9.5 million from $5.4 million year-over-year due to higher production volume.

Outlook and guidance

• Cash runway projected through 2028, supported by anticipated proceeds from divestiture, Sagard, and Bora transactions.

• Ongoing cost-reduction initiatives and anticipated partner payments expected to further extend runway.

• Multiple clinical data updates and milestones for ADC and TCE programs expected throughout 2026 and into 2027.

• Additional product candidate nominations planned by end of 2026.